**COVID-19 Testing CPT/HCPCS Codes**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **CPT/ HCPCS Code** | **Description** | **Created Date/ Effective Date (if differs)** | **CMS Payment** | **CMS/AMA Information** | **Reference Documents** |
| **Molecular Detection Codes** | | | | | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | 02/13/2020/ eff 02/04/20 | $35.91 | * Use for CDC test kit |  |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 03/05/2020/ eff 02/04/20 | $51.31 | * Use for methods not specified by U0001 or 87635. * Can use this code in place of 87635 for time being. * If test kit allows "point of care" type use, can apply modifier QW |  |
| 87635 | Infectious agent detection by nucleic acid (DNA or RNA); **severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]),** amplified probe technique | 03/13/2020 | $51.31 (published 5/19/20) | * If test kit allows "point of care" type use, can apply modifier QW   Appropriate for   * Abbott ID Now (Lab 7901) * Cepheid Xpert Xpress * BioFire Torch * Cepheid GeneXpert |  |
| 87636 | Infectious agent detection by nucleic acid (DNA or RNA); **severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B,** multiplex amplified probe technique | Created 10/6/2020 | FirstCoast $142.63 | * Refer to the Molecular testing panel codes below for additional PLA codes for specific test kits. |  |
| 87637 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome **coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus**, multiplex amplified probe technique | Created 10/6/2020 | FirstCoast $142.63 | * Refer to the Molecular testing panel codes below for additional PLA codes for specific test kits |  |
| U0003 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R | 04/14/2020 | $100 | * High throughput technology is an automated instrument that can process at least 200 specimens a day. Examples as of 4/14 include:   + Roche cobas 6800 System,   + Roche cobas 8800 System   + Abbott m2000 System   + Hologic Panther Fusion System   + GeneXpert Infinity System   + NeuMoDx 288 Molecular   + NeuMoDx 96 Molecular * Use for tests that would have been identified by 87635   Appropriate for:   * Abbott RealTime SARS-CoV-2 assay (Lab 7887) * Warde in-house COVWD using Abbott m2000 * Quest (Warde COV19) * NxtGn reference lab used by West MI using ThermaFisher QuantStudio |  |
| U0004 | 2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R. | 04/14/2020 | $100 | * High throughput technology is an automated instrument that can process at least 200 specimens a day. Examples as of 4/14 include:   + Roche cobas 6800 System,   + Roche cobas 8800 System   + Abbott m2000 System   + Hologic Panther Fusion System   + GeneXpert InfinitySystem   + NeuMoDx 288 Molecular * Use for tests that would have been identified by U0002 |  |
| **Molecular Testing Panel Codes that include COVID-19** | | | | | |
| 0202U | Infectious disease (bacterial or viral respiratory tract infection), pathogen specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected | 05/20/2020 | MAC priced until further notice  FirstCoast $416.78 | * Code describes a multiplex amplified probe test that provides qualitative identification of 22 respiratory viral and bacterial pathogens from a single specimen obtained using nasopharyngeal swabs. * PLA Code: BioFire® Respiratory Panel 2.1 * CMS recognized the code in CR11815 dated June 12, 2020 * Several MACs have LCDs that indicate these large respiratory viral panels are non-covered. |  |
| 0223U | Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected | 06/25/2020 | MAC priced until further notice  FirstCoast $416.78 | * Describes a novel type of fully automated molecular assay that pro­vides simultaneous qualitative detection and identification of multiple respiratory patho­gens based on viral and bacterial nucleic acids obtained via nasopharyngeal swabs. * To report a PLA code, the analysis performed must ful­fill the code descriptor and must be the test represented by the proprietary name listed in Appendix O. Codes 0223U will be listed in Appendix O as follows:   + QIAstat-Dx Respiratory SARS-CoV-2 Panel, QIAGEN Sciences, QIAGEN GMbHb * Several MACs have LCDs that indicate these large respiratory viral panels are non-covered. |  |
| 0225U | Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected | 08/10/2020 | MAC priced until further notice  FirstCoast $416.78 | * PLA code: ePlex® Respiratory Pathogen Panel 2, GenMark Dx, GenMark Diagnostics, Inc * CMS recognized the code in CR11937/Trans 10318 dated 08/21/2020 * Several MACs have LCDs that indicate these large respiratory viral panels are non-covered. |  |
| 0240U | Infectious disease (viral respiratory tract infection), pathogen-specific RNA, **3 targets** (**severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B),** upper respiratory specimen, each pathogen reported as detected or not detected | Created 10/6/2020 | FirstCoast $142.63 | * PLA code: Xpert® Xpress SARS-CoV-2/ Flu/RSV (SARS-CoV-2 & Flu targets only), Cepheid |  |
| 0241U | Infectious disease (viral respiratory tract infection), pathogen-specific RNA**, 4 targets** (**severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]),** upper respiratory specimen, each pathogen reported as detected or not detected | Created 10/6/2020 | FirstCoast $142.63 | * PLA code: Xpert® Xpress SARS-CoV-2/ Flu/RSV (all targets), Cepheid |  |
|  | | | | | |
| **Antigen Testing Codes** | | | | | |
| 87426 | Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV, SARS-CoV-2 [COVID-19]) | 06/25/2020 | MAC priced until further notice  FirstCoast $45.23 | * This code and testing is not specific for SARS-CoV-2. Current assays are not able to distinguish between SARS-CoV and SARS-CoV-2. * BD Veritor System |  |
| 87811 | Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) | Created 10/6/2020 | FirstCoast $41.38 | * BinaxNow COVID-19 Ag Card |  |
|  |  |  |  |  |  |
|  | | | | | |
| **Antibody Testing Codes** | | | | | |
| 86328 | Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, **single step** method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) | 04/10/2020 | $45.23 (published 05/19/20) | * Use for single step methods * Report only once for a reagent strip assay, even if multiple antibody classes are detected. |  |
| 86769 | Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) | 04/10/2020 | $42.13 (published 05/19/20) | * Use for multiple step methods * Equipment verified   + Diasorin Liaison XL |  |
| 86413 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative | 09/08/2020 | FirstCoast $42.13 | * Used for quantitative antibody testing * CMS recognized this conde in CR 11937/Trans 10367 dated 09/24/2020 |  |
| 86408 | Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen | 08/10/2020 | MAC priced until further notice  FirstCoast $42.13 | * CMS recognized the code in CR11937/Trans 10318 dated 08/21/2020 |  |
| 86409 | Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]);titer | 08/10/2020 | MAC priced until further notice  FirstCoast $105.33 | * CMS recognized the code in CR11937/Trans 10318 dated 08/21/2020 |  |
| 0224U | Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed | 06/25/2020 | MAC priced until further notice  FirstCoast $42.13 | * Describes qualita­tive and quantitative detection of antibodies in serum and plasma. The test may aid in determining whether an individual suspected of significant exposure or prior infection with SARS-CoV-2 virus has a high titer of IgG antibodies against this virus when performed. * To report a PLA code, the analysis performed must ful­fill the code descriptor and must be the test represented by the proprietary name listed in Appendix O. Codes 0224U will be listed in Appendix O as follows:   + COVID-19 Antibody Test, Mt Sinai, Mount Sinai Laboratory * Do not report 0224U in conjunction with 86769 |  |
| 0226U | Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum | 08/10/2020 | MAC priced until further notice  FirstCoast $42.28 | * PLA Code: Tru-ImmuneTM, Ethos Laboratories, GenScript® USA Inc * CMS recognized the code in CR11937/Trans 10318 dated 08/21/2020 |  |

MAC payment amounts: 